Early PSA response to antiandrogen therapy in metastatic castration-resistant prostate carcinoma patients: A predictive marker for progression-free survival?


Atakan D., Ozkan A., Guven M. A. , Sinan K.

JOURNAL OF BUON, vol.25, no.3, pp.1625-1630, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 3
  • Publication Date: 2020
  • Title of Journal : JOURNAL OF BUON
  • Page Numbers: pp.1625-1630

Abstract

Purpose: Enzalutamide and abiraterone acetate (AA) are the main therapeutic approaches for the treatment of metastatic castration-resistant prostate cancer (mCRPC) after the failure of androgen deprivation therapy during or following docetaxel-based chemotherapy. The aim of the present study was to investigate the role of early prostate-specific antigen (PSA) decline (four weeks after anti-androgen therapy) in predicting long-term progression free survival (PFS).